Want to see LONA full AI Analyst Report?
LeonaBio (LONA) AI Stock Analysis
Top Page
LeonaBio
(NASDAQ:LONA)
The score is held down primarily by weak financial performance (pre-revenue, widening losses, and ongoing cash burn). Technicals are mixed but still broadly below key longer-term moving averages with a negative MACD. Corporate events add some support via Phase 3 progress and potential capital from warrant exercises, while valuation metrics are limited due to a negative P/E and no dividend yield data.
LeonaBio (LONA) vs. SPDR S&P 500 ETF (SPY)
- Market Cap
- $18.85M
- Dividend Yield
- ―
- Average Volume (3M)
- 196.74K
- Price to Earnings (P/E)
- -0.1
- Beta (1Y)
- 1.21
- Revenue Growth
- ―
- EPS Growth
- -49.65%
- Country
- US
- Employees
- 19
- Sector
- Healthcare
- Sector Strength
- 51
- Industry
- Biotechnology
LeonaBio Business Overview & Revenue Model
Company Description
LeonaBio, Inc. operates as a biopharmaceutical firm engaged in clinical-stage development. Its core mission revolves around crafting small molecule therapies aimed at revitalizing neurological function and arresting the advancement of neurodegenerati...
LeonaBio Financial Statement Overview
Summary
Overall financials are weak: the company is pre-revenue (revenue is 0) with sizable and worsening losses (TTM net loss ~141.5M vs ~105.6M in 2025) and consistent cash burn (TTM operating cash flow ~-61.9M). The main offset is low leverage (debt-to-equity ~0.02), but equity has declined sharply over time, increasing financing/dilution risk.
Income Statement
8Very NegativeBalance Sheet
55NeutralCash Flow
18Very Negative| Breakdown | TTM | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 0 | 0 | 0 | 0 | 0 | 0 |
| Gross Profit | -68.56M | -68.09M | 0 | 0 | 0 | -479.00K |
| EBITDA | -53.29M | -33.21M | -95.81M | -125.97M | -88.01M | -54.37M |
| Net Income | -141.46M | -105.61M | -96.94M | -117.67M | -95.64M | -54.85M |
Balance Sheet | ||||||
| Total Assets | 56.89M | 92.15M | 58.78M | 160.25M | 258.15M | 332.01M |
| Cash, Cash Equivalents and Short-Term Investments | 51.07M | 88.33M | 51.27M | 147.42M | 200.34M | 253.76M |
| Total Debt | 577.00K | 803.00K | 1.22M | 1.58M | 1.91M | 1.92M |
| Total Liabilities | 23.30M | 64.36M | 13.94M | 30.06M | 23.02M | 10.92M |
| Stockholders Equity | 33.59M | 27.79M | 44.84M | 130.19M | 235.14M | 321.08M |
Cash Flow | ||||||
| Free Cash Flow | -61.93M | -45.73M | -97.20M | -101.06M | -73.61M | -44.67M |
| Operating Cash Flow | -61.93M | -45.73M | -97.17M | -100.75M | -72.47M | -43.10M |
| Investing Cash Flow | -8.19M | -15.89M | 54.83M | 95.09M | 57.66M | -4.08M |
| Financing Cash Flow | 82.55M | 82.46M | 194.00K | 493.00K | 654.00K | 97.09M |
LeonaBio Technical Analysis
Price Trends
Market Momentum
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For LONA, the sentiment is Negative. The current price of 4.94 is below the 20-day moving average (MA) of 5.37, below the 50-day MA of 6.05, and below the 200-day MA of 7.51, indicating a bearish trend. The MACD of -0.28 indicates Negative momentum. The RSI at 43.73 is Neutral, neither overbought nor oversold. The STOCH value of 32.22 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for LONA.
LeonaBio Risk Analysis
LeonaBio disclosed 91 risk factors in its most recent earnings report. LeonaBio reported the most risks in the "Tech & Innovation" category.
Latest Risks Added
3 New RisksLeonaBio Peers Comparison
Overall Rating
IMRN53Neutral
CLRB48Neutral- LONA47Neutral
COCP45Neutral
BIVI37.6Underperform
Financial Indicators
| Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
| IMRN | 53Neutral | $9.08M | -3.10 | -31.88% | ― | 10.41% | 42.44% |
| Sector * | 51Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% |
| CLRB | 48Neutral | $11.39M | -0.26 | -165.71% | ― | ― | 77.68% |
| LONA | 47Neutral | $46.54M | -0.14 | -411.58% | ― | ― | -49.65% |
| COCP | 45Neutral | $19.17M | -1.24 | -207.47% | ― | ― | 38.55% |
| BIVI | 38Underperform | $12.20M | -0.45 | -126.02% | ― | ― | 78.51% |
* Healthcare Sector Average
Performance Comparison
| Show on chart | Ticker | Company Name | Price | Change | % Change |
|---|---|---|---|---|---|
| LONA | Leonabio, Inc. | 4.94 | 0.76 | 18.18% | |
| CLRB | Cellectar Biosciences Inc | 1.21 | -2.09 | -63.48% | |
| IMRN | Immuron | 0.88 | -1.12 | -56.00% | |
| COCP | Cocrystal Pharma | 0.99 | -0.10 | -8.72% | |
| BIVI | Biovie Inc. | 1.43 | -0.28 | -16.37% |
LeonaBio Corporate Events
LeonaBio Opens Warrant Exercise Window for New Capital
PositiveIn December 2025, LeonaBio, Inc. issued Series A Common Warrants in a private placement, covering an aggregate of 23,031,494 shares of common stock at an exercise price of $6.35 per share, underscoring the company’s continued use of structured...
LeonaBio Reaches Key Phase 3 Enrollment Milestone
PositiveOn August 26, 2026, LeonaBio reported enrollment of the 500th patient in its Phase 3 ELAINE-3 trial evaluating lasofoxifene with abemaciclib in a hard-to-treat subset of metastatic breast cancer, marking a significant clinical milestone for its lead...
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.
Date of analysis: Oct 13, 2026